Pacira BioSciences Business Summary

Pacira BioSciences, Inc. (PCRX) is a specialty pharmaceutical leader focused on non-opioid pain management, generating revenue primarily through the direct sale of proprietary analgesic products and medical devices to hospitals and ambulatory surgery centers. The company’s business model is anchored by three core segments: its flagship long-acting local anesthetic EXPAREL, the osteoarthritis-focused injectable ZILRETTA, and the iovera° handheld cryoanalgesia system. As of March 2026, Pacira’s growth is catalyzed by the NOPAIN Act, which provides separate Medicare reimbursement for non-opioid treatments in outpatient settings, and its "5x30" strategic initiative aimed at treating 3 million patients annually by 2030. Within the competitive landscape, Pacira maintains a dominant market share in the long-acting infiltration space but faces intensifying pressure from Heron Therapeutics (Zynrelef), Vertex Pharmaceuticals (Suzetrigine), and Supernus Pharmaceuticals. While historically a niche leader, Pacira is currently pivoting toward a broader biopharmaceutical platform through strategic partnerships, such as its 2025 ZILRETTA co-promotion deal with J&J MedTech. The company is led by Chief Executive Officer Frank D. Lee, a Genentech veteran and former CEO of Forma Therapeutics who assumed leadership in 2024 to spearhead commercial scaling and pipeline diversification. The executive team includes Chief Financial Officer Shawn Cross, Chief Commercial Officer Brendan Teehan, and Chief Business Officer Krys Corbett, bringing collective expertise from organizations such as Acadia Pharmaceuticals and Lyell Immunopharma. Governance is overseen by Board Chair Laura Brege, who succeeded Paul Hastings in January 2025 amidst a broader board refreshment strategy that saw five new independent directors join since late 2023. Originally founded by Dr. Gary Pace, the company is now largely supported by institutional investors including BlackRock, Vanguard, and State Street. This leadership cohort is focused on defending EXPAREL’s exclusivity runway through 2039 via recent patent settlements and expanding the company’s international footprint through regional partnerships like LG Chem in the Asia-Pacific market.